ABSTRACT The aminoglycosides are highly effective broad-spectrum antimicrobial agents. However, their efficacy is diminished due to enzyme-mediated covalent modification, which reduces affinity of the drug for the target ribosome. One of the most prevalent aminoglycoside resistance enzymes in Gram-negative pathogens is the adenylyltransferase ANT(2؆)-Ia, which confers resistance to gentamicin, tobramycin, and kanamycin. Despite the importance of this enzyme in drug resistance, its structure and molecular mechanism have been elusive. This study describes the structural and mechanistic basis for adenylylation of aminoglycosides by the ANT ( IMPORTANCE To successfully manage the threat associated with multidrug-resistant infectious diseases, innovative therapeutic strategies need to be developed. One such approach involves the enhancement or potentiation of existing antibiotics against resistant strains of bacteria. The reduction in clinical usefulness of the aminoglycosides is a particular problem among Gramnegative human pathogens, since there are very few therapeutic options for infections caused by these organisms. In order to successfully circumvent or inhibit the activity of aminoglycoside-modifying enzymes, and to thus rejuvenate the activity of the aminoglycoside antibiotics against Gram-negative pathogens, structural and mechanistic information is crucial. This study reveals the structure of a clinically prevalent aminoglycoside resistance enzyme [ANT(2؆)-Ia] and depicts the molecular basis underlying modification of antibiotic substrates. Combined, these findings provide the groundwork for the development of broadspectrum inhibitors against antibiotic nucleotidyltransferases.
Members of the aminoglycoside family that contain a 2-deoxystreptamine (2-DOS) core, such as gentamicin, kanamycin, and tobramycin (Fig. 1A) , have been particularly effective against many Gram-negative bacterial pathogens. This class of aminoglycoside is decorated at positions 4 and 6 of the 2-DOS core with amino-modified sugars; these substituents are referred to as the prime and double-prime rings, respectively. Such 4,6-disubstituted aminoglycosides bind to 16S rRNA; in particular, the double-prime ring exhibits key interactions with G1405 of the 16S rRNA (Fig. 1B) (6, 7) .
Despite the broad-spectrum activity and clinical success of these drugs, their usefulness in the control of bacterial infections has been overshadowed by the emergence of resistance. Indeed, these drugs are inactivated by a variety of resistance mechanisms. The most common mechanism is covalent modification of the drug, a process that renders the antibiotic unable to bind effectively to the ribosome and thus alleviates the drug-induced translation interference (8) . Aminoglycoside inactivation is catalyzed by a plethora of aminoglycoside-modifying enzymes (AMEs) that operate by different molecular mechanisms, including phosphorylation (catalyzed by nucleoside triphosphate-dependent O-phosphotransferases [APHs]), acetylation (catalyzed by acylcoenzyme A-dependent N-acetyltransferases [AACs] ) and adenylylation (catalyzed by nucleoside triphosphate-dependent O-nucleotidyltransferases [ANTs]) (9) .
Structural and biochemical knowledge of these modifying enzymes is crucial for the development of strategies to circumvent their activity and to thus rejuvenate the antibacterial action of the aminoglycosides (10) . To date, there have been significant advances providing structural, mechanistic, and inhibitory insight into many members of the APH enzymes (11, 12) . The AAC family has also been well characterized through structure-function studies of AAC (3) and AAC(6=) enzymes (13) (14) (15) (16) (17) (18) (19) (20) . In contrast, the ANT family of enzymes is not well characterized (11) , and there are only three ANT enzymes with determined crystal structures: ANT(4=)-Ia (PDB ID: 1KNY) (21), ANT(4=)-IIb (PDB ID: 4EBJ and 4EBK), and ANT(6)-Ia (PDB ID: 2PBE).
There are five main classes of ANT enzymes, defined by their regioselectivity of chemical modification at positions 2Љ, 3Љ, 4=, 6, and 9 of substrate aminoglycosides. The aminoglycoside 2Љ-Onucleotidyltransferase [ANT(2Љ)-Ia] was originally identified within a clinical isolate of Klebsiella pneumoniae in 1971 (22) and is now one of the most clinically prevalent ANT enzymes harbored by Gram-negative pathogens in North America (23) (24) (25) . This allele has spread to many other bacterial genera, including Pseudomonas, Acinetobacter, and Enterobacter, all members of the socalled ESKAPE pathogens, which have been designated highly clinically important (26, 27) .
ANT(2Љ)-Ia confers antibiotic resistance by magnesiumdependent transfer of a nucleoside monophosphate (AMP) to the 2Љ-OH of aminoglycoside substrates (Fig. 1A) (28) . ANT(2Љ)-Ia is one of the few AMEs that modify a hydroxyl moiety on the double-prime ring. Understanding the molecular basis of ANT(2Љ)-Ia-mediated drug inactivation is vital to help guide the development of new aminoglycoside-like antibiotics such as plazomicin (29) and for the identification of inhibitors targeting AMEs, which could rescue the activity of older aminoglycoside drugs such as gentamicin. Here we report the three-dimensional (3D) structure of ANT(2Љ)-Ia and propose a molecular mechanism of adenylylation mediated by this widespread resistance element. (30) (31) (32) (33) (34) indicated that expression of ANT(2Љ)-Ia in Escherichia coli resulted in only partially soluble recombinant protein. We expressed the enzyme in fusion with glutathione S-transferase (GST), which resulted in significant improvement in expression of soluble protein, allow- ing us to obtain pure ANT(2Љ)-Ia (Ͼ95% homogeneity) after removal of the N-terminal GST moiety (see Materials and Methods). To confirm the activity of recombinant ANT(2Љ)-Ia, we used the EnzChek pyrophosphatase assay, which allows continuous measurement of the release of pyrophosphate by ANT(2Љ)-Ia by coupling it to the colorimetric detection of phosphate in the presence of excess pyrophosphatase. Accordingly, ANT(2Љ)-Ia kinetic parameters (Table 1) were consistent with previous reports (33) , indicating that the protein retained full activity and was suitable for structural and mechanistic studies.
RESULTS

Purification of ANT(2؆)-Ia. Previous reports
Structural characterization of ANT(2؆)-Ia reveals the molecular framework for its activity. To decipher the mechanism underlying adenylylation of 4,6-disubstituted 2-DOS-containing aminoglycosides by ANT(2Љ)-Ia, we sought to determine the crystal structure of the protein alone and in complex with a substrate aminoglycoside. The apoenzyme structure was solved using the sulfur single-anomalous-dispersion (S-SAD) phasing method. The protein crystallized with one molecule per asymmetric unit, and the apo structure was refined to 1.48 Å. The ANT(2Љ)-Iakanamycin B cocrystal complex was solved by molecular replacement (MR) using the apoenzyme as the search model and refined to 1.73 Å. The final models of ANT(2Љ)-Ia contained interpretable electron density for residues 3 to 177 (refinement statistics can be found in Table 2 ).
The structure of ANT(2Љ)-Ia reveals that the protein comprises two main domains: a larger N-terminal domain (residues 3 to 92) that is centered on a ␤-sheet with three interspersed ␣-helices and a C-terminal domain (residues 93 to 177) that contains two ␤-hairpins followed by four ␣-helices forming a bundle (Fig. 2) . The general conformation of the N-terminal domain of ANT(2Љ)-Ia ( Fig. 2) follows the ␣1-␤1-␣2-␤2-X-␤4-␤3 NT fold topology (where X corresponds to a variable insert across nucleotidyltransferase [NT] fold-containing proteins), which is typical of this group of proteins (35) . The C-terminal domain adopts two ␤-hairpins, with the first forming an interaction on one edge of the NT domain core ␤-sheet, plus a bundle of three ␣-helices. ANT(2؆)-Ia-kanamycin B complex structure reveals the specifics of antibiotic substrate recognition. The apo and kanamycin B-bound structures of ANT(2Љ)-Ia align with a root mean square deviation (RMSD) of 0.15 Å across 159 matching C␣ atoms, indicating that no gross conformational rearrangements occur upon aminoglycoside binding. The NT and C-terminal domains of ANT(2Љ)-Ia form the walls of a large cleft~28 Å in diameter (Fig. 3A) , which in the case of the kanamycin B-bound structure harbors unambiguous additional electron density corresponding to the antibiotic molecule. The central ring of the antibiotic is directed toward the interior of the protein, and the prime and double-prime rings point toward solvent (Fig. 3A (Fig. 3B) . Notably, both Mg 2ϩ ions in the ANT(2Љ)-Ia active site lack a sixth coordinating ligand.
According to the ANT(2Љ)-Ia-kanamycin B complex structure, the antibiotic molecule is anchored in the enzyme active site through eight hydrogen bonds formed between side chain or main-chain atoms belonging to a total of nine residues (Fig. 3B) . On the substrate side, hydrogen bonds are formed by the hydroxyl/amino groups that face the interior of the active site (Fig. 3B) . Importantly, both the NT fold and the C-terminal domains of ANT(2Љ)-Ia contribute residues involved in binding the antibiotic substrate. The enzyme also forms two major stacking interactions between aromatic side chains and the antibiotic, with Tyr 74 and Tyr 134 situated over the central 2-DOS ring and the prime rings of kanamycin B, respectively. Electron density corresponding to the 6Љ carbon and 6Љ-OH atoms of kanamycin B was relatively poorly defined, likely due to the lack of interactions between ANT(2Љ)-Ia and this area of the substrate. Overall, our analysis of the ANT(2Љ)-Ia-kanamycin B structure showed that the enzyme's active site forms interactions with all three rings of the aminoglycoside substrate. These interactions effectively secure the position of the 2Љ-OH nucleotidylation site in close proximity to the Mg I 2ϩ ion and the remainder of the deep active-site cleft, which is adequate in size to accommodate a nucleoside triphosphate (Fig. 3A) .
ANT ( (Fig. 4A) . However, Lnu(A) lacks an equivalent of the C-terminal ␣-helix in ANT(2Љ)-Ia (residues 166 to 177). Importantly, the similarity between these two enzymes extends to the molecular composition of their active sites, including the positions of the Mg 2ϩ -coordinating residues, which in both enzymes also coordinate the substrate antibiotic ring to be adenylylated (Fig. 4B) . In regard to the ANT(2Љ)-Ia-kanamycin B complex structure, the antibiotic appears to be more solvent exposed than lincomycin bound to Lnu(A); this observation is likely explained by the highly polar properties of the aminoglycosides. Furthermore, ANT(2Љ)-Ia residues conferring interactions with the antibiotic substrate are markedly different from their equivalents in Lnu(A).
We also observed significant structural similarity (Z score of 6.7 and C␣ RMSD of 3.4 Å across 109 matching C␣ atoms) between ANT(2Љ)-Ia and the lincosamide nucleotidyltransferase LinB (36) , an enzyme that also features the NT fold domain (see Fig. S1 in the supplemental material). As observed between ANT(2Љ)-Ia and Lnu(A), residues of LinB coordinating the Mg 2ϩ ions (Asp 40 and Asp 42 ) and the third acidic residue (Glu 89 ) are conserved (see Fig. S1 ); however, the C-terminal domains of ANT(2Љ)-Ia and LinB do not show any structural similarity.
Interestingly, our homology search also revealed similarity between the NT fold of ANT(2Љ)-Ia and DNA polymerase ␤ (Pol␤) (the palm domain) (37-39) (Fig. 4) , a relationship that was also noted with ANT(4=) (21) . As we observed between ANT(2Љ)-Ia, Lnu(A), and LinB, the structural similarity with DNA Pol␤ extends to the architecture of the catalytic center (Fig. 4B) . The three acidic residues, two Mg 2ϩ ions, and position of the nucleotidylation sites (3=-OH from the primer DNA for Pol␤) spatially colocalize. In the polymerization reaction catalyzed by DNA Pol␤, Asp 256 is considered the catalytic base that activates the primer DNA 3=-OH for nucleophilic attack on the ␣-phosphate of incoming nucleoside triphosphates (40) . However, beyond this domain, DNA Pol␤ contains additional N-and C-terminal domains that do not share any structural similarity with ANT(2Љ)-Ia.
Finally, the structures of ANT(4=)-Ia, ANT(4Љ)-IIb, and ANT(6)-Ia enzymes were also identified as ANT(2Љ)-Ia homologs that share the conserved NT fold. However, the orientation of the aminoglycoside substrates, the architecture of the C-terminal domains, and their oligomeric state (dimeric) differ dramatically from those of ANT(2Љ)-Ia.
Site-directed mutagenesis confirms individual roles of ANT(2؆)-Ia active-site residues. To investigate the role of ANT(2Љ)-Ia active-site residues in catalysis and substrate recognition, we individually replaced them with alanine residues and tested the activities of corresponding enzyme variants in vitro. The Asp 44 -to-Ala substitution resulted in complete loss of ANT(2Љ)-Ia activity against both kanamycin B and ATP, even at substrate concentrations 5 times the K m ( Table 1) . Mutation of Asp 86 to Ala likewise rendered the enzyme entirely inactive (Table 1) .
We attempted to determine a nucleoside triphosphate/ analogue-bound complex structure of ANT(2Љ)-Ia but were not successful. Due to similarities in the active sites of LinB and ANT(2Љ)-Ia, the ternary structure of the former (36) was used to assist in the identification of residues that may be important in nucleotide binding. This comparison identified the positively charged residues Arg 40 and His 42 as likely candidates; indeed, replacement of His 42 resulted in loss of all enzyme activity (Table 1) . However, Arg 40 only marginally reduced the nucleotidyltransferase activity. To ascertain the effect of Arg 40 substitution on nucleotide and kanamycin B binding, kinetic parameters were determined for both. For kanamycin B, the kinetics did not differ significantly from those of the wild-type enzyme, but nucleotide binding appeared to be impaired (Table 1) . These findings implicate His 42 and Arg 40 in the function of ANT(2Љ)-Ia. Due to their distance from the kanamycin B 2Љ-OH group (10 and 13 Å, respectively), these residues are not involved in catalysis but instead likely coordinate ATP.
DISCUSSION
We present the structural and mechanistic characterization of the ANT(2Љ)-Ia enzyme in complex with its antibiotic substrate. The chemical modification of the 2Љ-OH provides the molecular logic for antibiotic resistance based on the importance of this site for interaction with the drug target (Fig. 1B) (28) . Combining all of our findings allows the proposal of a mechanism for adenylylation by ANT(2Љ)-Ia (Fig. 5) . The putative mechanism of ANT(2Љ)-Ia parallels the well-studied mechanism of DNA polymerization by DNA Pol␤ (40) . Binding of the nucleoside triphosphate groups is stabilized by the two Mg 2ϩ ions in the active site, His 42 and Arg 40 , plus perhaps other nearby residues, such as Lys 147 and His 148 . A catalytic base is predicted to be involved in a direct AMP transfer mechanism from ATP to the aminoglycoside, via activation of the 2Љ-OH. Our mutagenic and structural data suggest Asp 86 as a likely candidate, due to the fact that it is essential for catalysis and that its interactions with the 2Љ-OH of the aminoglycoside would provide electrophilic polarization, increasing the nucleophilicity of the alcohol. The interaction of Mg II 2ϩ with the substrate 2Љ-OH would also lend electrophilic polarization to this group. In general, this chemical environment feature is consistent with a nucleophilic attack on the ␣-phosphate of the nucleoside triphosphate by the substrate 2Љ-OH. Collapse of a tetrahedral intermediate would release the energetic pyrophosphate as a suitable leaving group.
Catalysis relies on coordination of Mg 2ϩ ions, positioning of the substrate ring targeted for modification, and the presence of a catalytic base. We observed that these active-site residues are con- served among other antibiotic nucleotidyltransferases, including Lnu(A), LinB, ANT(4=)-Ia, ANT(4Љ)-Ib, and ANT(6)-Ia (36) . The similarity of catalytic architecture among these enzymes with that of DNA Pol␤, which was previously noted for LinB (36) , is consistent with a shared catalytic mechanism utilized by these enzymes. In turn, these observations suggest an evolutionary relationship between ANT(2Љ)-Ia, Lnu(A), LinB, and DNA Pol␤ enzymes, with divergent evolution of the NT fold toward adaptation for activity against chemically distinct substrates. Clearly, substrate specificity dramatically differs and this diversification appears to be conferred by distinct C-terminal domains.
We anticipate that since ANT and Lnu enzymes share clear structural and catalytic similarities, as revealed through this study, it may be possible to develop broad-spectrum inhibitors against antibiotic nucleotidyltransferases. This strategy would rejuvenate multiple classes of antibiotics that are susceptible to inactivation via nucleotidylation. To allow for this possibility, it is necessary for these inhibitors to target the core nucleotidyltransferase catalytic machinery, since targeting the substrate recognition domain would be less fruitful. This study will allow such focused efforts, leading the way for structure-based drug design and the development of next-generation antibiotics that are recalcitrant to adenylylation.
MATERIALS AND METHODS
Overexpression and purification of ANT(2؆)-Ia. E. coli Rosetta (Merck KGaA, Darmstadt, Germany) (DE3; pDEST15:aadB) (aadB, GenBank no. ACX70191.1) was used for overexpression of ANT(2Љ)-Ia as a GST fusion product as previously described (41) . Glutathione affinity chromatography was utilized as an initial purification step in buffer A (20 mM Tris [pH 8.0], 300 mM NaCl), and the GST fusion tag was removed by tobacco etch virus (TEV) protease cleavage at 12°C, followed by elution of the cleaved protein with buffer A. ANT(2Љ)-Ia was purified to high homogeneity (Ͼ95%) by the inclusion of a final purification step involving gel filtration chromatography. Separation was carried out at 4°C using a HiPrep S200 (26/60) prepacked column (GE Healthcare), and samples were eluted in buffer A (20 mM Tris [pH 8.0], 300 mM NaCl, 1 mM dithiothreitol [DTT], and 5 mM MgCl 2 ). For determination of the oligomeric state of ANT(2Љ)-Ia, the column was calibrated using a gel filtration LMW calibration kit (GE Healthcare) using the manufacturer's guidelines. ANT(2Љ)-Ia eluted as a single well-defined peak corresponding to a monomeric form and a molecular mass of~20 kDa; accordingly, analysis of all crystal structure contacts using the PDBePISA server (42) did not reveal any oligomeric assemblies.
Crystallization of ANT(2؆)-Ia and data collection. ANT(2Љ)-Ia was concentrated to 60 mg/ml, and crystals were grown at 20°C from hanging drops using the vapor diffusion method. Optimized crystallization conditions for ANT2(2Љ)-Ia were 10% 2-propanol, 20% polyethylene glycol (PEG) 4000, and 0.1 M HEPES (pH 7.5). ANT(2Љ)-Ia was cocrystallized with kanamycin B (Sigma Aldrich, Oakville, ON, Canada) at a ratio of 5 times the molar concentration of the former. For data collection, the crystals were passaged through mother liquor containing 20% (vol/vol) glycerol and frozen in nitrogen.
Data were collected at 100 K with Cu K␣ X rays generated by a Rigaku 007 Microfocus rotating-anode generator equipped with VariMax HF optics and a Rigaku Raxis IV2ϩ detector. All X-ray data were reduced with HKL-3000 (43) . The ANT(2Љ)-Ia apoenzyme structure was solved by S-SAD using Phenix.solve (44) ; four of the six sulfur sites (four cysteine residues) were located. Automated model building was performed with Phenix.autobuild, refinement was performed using Phenix.refine, and manual model building was performed with Coot (45) . The ANT(2Љ)-Iakanamycin B complex structure was solved by molecular replacement (MR) using the apoenzyme structure. Fo-Fc difference density corresponding to the aminoglycoside molecule was readily traceable after MR. Translation-libration-screw rotation (TLS) parameterization was utilized for refinement of both structures. Geometries were verified using the Phenix and Coot validation tools and the RCSB PDB deposition server. Occupancy values for solvent molecules and Mg 2ϩ atoms were refined. All B factors were refined as isotropic. Average B factor and bond angle/bond length RMSD values were calculated using Phenix.
Structure analysis. For comparison of similar structures, the C␣ RMSD was calculated using the SSM superposition tool in Coot (46) and the Dali server (47) . The PDBePISA tool (42) was utilized to identify protein-ligand interactions. Structural homologs in the PDB were identified using the Dali server (47) . Secondary structure boundaries were generated using the PDBsum server (48) .
Site-directed mutagenesis. QuikChange (Agilent Technologies, Mississauga, Canada) site-directed mutagenesis was used to introduce point mutations within aadB in the pDEST15 vector (Life Technologies), according to the manufacturer's suggested guidelines. Primers were designed using the QuikChange primer design program (Agilent Technologies). Resulting mutants were confirmed by sequencing at the MOBIX Central Facility (McMaster University, Hamilton, Canada).
ANT(2؆)-Ia steady-state kinetic studies. The continuous EnzChek pyrophosphate assay (Life Technologies) was used to assess wild-type and mutant ANT(2Љ)-Ia enzyme activity in vitro. The reaction was followed at 360 nm using a Spectramax Plus 384 (Molecular Devices) microtiter plate reader. The assay was performed in duplicate, in 96-well plates (Nunc, ThermoScientific) with a final volume of 100 l and 50 mM HEPES [pH 7.5], 40 mM KCl, 10 mM MgCl 2 , and 5 g of ANT(2Љ)-Ia. For char-acterization of kanamycin B, ATP was kept at 5 times the K m , and for assessment of ATP dependence, kanamycin was also kept at 5 times the K m . The reaction mixtures were incubated with shaking for 3 min at 25°C, followed by initiation with nucleotide, and the formation of pyrophosphate was monitored for 10 min. Data were assessed using software in GraFit 5.0.13 (Erithacus Software).
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